PRNewsWire
11 Jun 2026, 01:52 UTC · 4h ago
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
PRNewsWire
11 Jun 2026, 01:52 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
Harbour BioMed has appointed Dr. Luisa Salter-Cid, a veteran of Flagship Pioneering and Bristol Myers Squibb, as a Scientific Advisor. — Adding high-level industry expertise in immunology and immuno-oncology can improve pipeline success rates and strategic direction, though advisory roles are less impactful than CEO/CFO changes.
+0.20Which stocks this story touches
The company has appointed a highly experienced scientific advisor to bolster its drug development pipeline.
Mentioned only as a former employer of the new advisor.
Mentioned only as a former employer of the new advisor.
Continue reading
6 related stories
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
9h ago
